Ticker
AFMD

Price
2.98
Stock movement up
+0.13 (4.56%)
Company name
Affimed NV
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
444.97M
Ent value
350.95M
Price/Sales
15.50
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-54.85%
3 year return
3.09%
5 year return
8.85%
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

AFMD does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales15.50
Price to Book-
EV to Sales12.23

FINANCIALS

Per share

Loading...
Per share data
Current share count149.32M
EPS (TTM)-
FCF per share (TTM)-

Income statement

Loading...
Income statement data
Revenue (TTM)28.71M
Gross profit (TTM)0.00
Operating income (TTM)-59.95M
Net income (TTM)-58.94M
EPS (TTM)-
EPS (1y forward)-0.76

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-208.82%
Profit margin (TTM)-205.30%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash169.85M
Net receivables4.55M
Total current assets180.93M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets193.25M
Accounts payable13.54M
Short/Current long term debt18.63M
Total current liabilities57.80M
Total liabilities75.83M
Shareholder's equity0.00
Net tangible assets115.84M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-98.98M
Capital expenditures (TTM)2.99M
Free cash flow (TTM)-101.97M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open2.90
Daily high3.00
Daily low2.83
Daily Volume1.03M
All-time high21.93
1y analyst estimate11.92
Beta2.43
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date27 Oct 2022

Downside potential

Loading...
Downside potential data
AFMDS&P500
Current price drop from All-time high-86.41%-12.18%
Highest price drop-94.41%-56.47%
Date of highest drop13 Dec 20179 Mar 2009
Avg drop from high-75.06%-11.38%
Avg time to new high80 days12 days
Max time to new high1791 days1805 days
COMPANY DETAILS
AFMD (Affimed NV) company logo
Marketcap
444.97M
Marketcap category
Small-cap
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Employees
197
Investor relations
-
SEC filings
CEO
Adolf Hoess
Country
USA
City
Heidelberg
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
September 12, 2022
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reachedStable disease was observed in 10 of 27 evaluable patien...
September 4, 2022
HEIDELBERG, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innat...
September 1, 2022
U.S. stock markets have been exceedingly volatile in 2022. The billionaire brothers Julian and Felix Baker -- co-owners of the biotechnology focused hedge fund Baker Bros. Advisors -- are a prime exa...
August 24, 2022
Does the August share price for Affimed N.V. ( NASDAQ:AFMD ) reflect what it's really worth? Today, we will estimate...
August 20, 2022
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 22.22% and 4.22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
August 11, 2022
AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022AFM13 combination with natural killer (NK) cells: On track to report updated...
August 11, 2022
HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innat...
August 4, 2022
With fears of a global recession rising, it’s natural that investors have turned their back on growth-intensive names. However, this backdrop has also yielded compelling undervalued biotech stocks to ...
July 25, 2022
Next page